AUROBINDO BUYS NEW JERSEY FACILITY FOR U.S. HEADQUARTERS

Indian drugmaker Aurobindo Pharma has acquired an FDA-compliant facility in Dayton, N.J. The facility spans 20 acres in the Princeton Life Sciences Corridor.

The new location will serve as an R&D, formulation, manufacturing and distribution facility, with potential for expansion. The campus will also serve as its U.S. headquarters.

The FDA recently granted Aurobindo tentative approval for its Didanosine chewable tablets for the treatment of HIV/AIDS.